



IFN- κ (V-14): sc-26217

BACKGROUND

Type I interferons (IFNs) include IFN- α , IFN- β , IFN- γ , IFN- δ , IFN- ω and IFN- κ . IFN- α and - β . These cytokines induce potent anti-viral activity. IFN- α and - β exert a variety of other biological effects, including anti-tumor and immunomodulatory activities. IFN- ω is a component of natural mixtures of IFN species produced by virus-induced leukocytes or Burkitt's lymphoma cells. IFN- κ is selectively expressed in epidermal keratinocytes. IFN- κ is upregulated in response to IFN- γ , IFN- β viral infection and double-stranded RNA. IFN- κ may play a role in regulating immune cell function. In both monocytes and dendritic cells, IFN- κ induction stimulates the release of several cytokines. The gene encoding human IFN- κ maps to the short arm of chromosome 9.

REFERENCES

- Adolf, G.R. 1987. Antigenic structure of human interferon ω 1 (interferon α II1): comparison with other human interferons. *J. Gen. Virol.* 68: 1669-1676.
- Hussain, M., Gill, D.S., and Liao, M.J. 1996. Identification of interferon- α 7, - α 14, and - α 21 variants in the genome of a large human population. *J. Interferon Cytokine Res.* 16: 853-859.
- Mire-Sluis, A.R., Page, L.A., Meager, A., Igaki, J., Lee, J., Lyons, S., and Thorpe, R. 1996. An anti-cytokine bioactivity assay for interferons- α - β and - ω . *J. Immunol. Methods* 195: 55-61.
- LaFleur, D.W., Nardelli, B., Tsareva, T., Mather, D., Feng, P., Semenuk, M., Taylor, K., Buergin, M., Chinchilla, D., Roshke, V., Chen, G., Ruben, S.M., Pitha, P.M., Coleman, T.A., and Moore, P.A. 2001. Interferon- κ a novel type I interferon expressed in human keratinocytes. *J. Biol. Chem.* 276: 39765-39771.
- Nardelli, B., Zaritskaya, L., Semenuk, M., Cho, Y.H., LaFleur, D.W., Shah, D., Ullrich, S., Girolomoni, G., Albanesi, C., and Moore, P.A. 2002. Regulatory effect of IFN- κ , a novel type I IFN, on cytokine production by cells of the innate immune system. *J. Immunol.* 169: 4822-4830.

SOURCE

IFN- κ (V-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of IFN- κ of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-26217 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

APPLICATIONS

IFN- κ (V-14) is recommended for detection of IFN- κ of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.